News round-up for 15 – 19 September by Bruno Quinney, Content Team at DDW. 

Stories from the drug discovery industry have continued to make headlines this week, with high-level investment from GSK in the US coming at a time when big pharma companies have halted investment in the UK. Elsewhere, there have been important developments in cancer research.  

The top stories: 

AstraZeneca halts £200m research investment in UK 

AstraZeneca has halted its planned £200 ($270) million investment in a research facility in Cambridge, UK, according to reports from Reuters. 

Read more… 

GSK to invest $30 billion in US over next five years 

GSK will invest $30 billion (£22 billion) across the US over the next five years in research and development and supply chain infrastructure, the company has announced. 

Read more… 

State-of-the-art life sciences hub opened in London 

Victoria House has been officially opened in London’s Bloomsbury Square as the capital’s state-of-the-art life sciences hub. 

Read more… 

New report calls for investment in UK research commercialisation 

A new research report has found that investing £15 billion ($20 billion) in UK university spinouts over the next 10 years could leverage a further £27 billion ($39 billion) of co-investment, leading to the creation of over 1700 additional spinouts and 56,000 skilled jobs, boosting UK science on the global stage. 

Read more… 

New data sheds light on immunotherapy failure in cancer patients 

A new study has revealed an important clue as to why immunotherapy fails in many patients with cancer. 

Read more…